68 Ga-DOTA-IBA Uptake in Breast cancer
- PMID: 38537211
- DOI: 10.1097/RLU.0000000000005200
68 Ga-DOTA-IBA Uptake in Breast cancer
Abstract
A 77-year-old woman with recently diagnosed breast cancer underwent 68 Ga-labeled DOTA-ibandronic acid ( 68 Ga-DOTA-IBA) PET/CT scan for the evaluation of bone metastases. The examination revealed increased tracer uptake, indicating that the cervical vertebrae presented osteoblastic metastasis. Interestingly, the breast cancer also showed enhanced activity of 68 Ga-DOTA-IBA.
Copyright © 2024 Wolters Kluwer Health, Inc. All rights reserved.
Conflict of interest statement
Conflicts of interest and sources of funding: none declared.
References
-
- Wang Y, Wang Q, Chen Z, et al. Preparation, biological characterization and preliminary human imaging studies of (68)Ga-DOTA-IBA. Front Oncol . 2022;12:1027792.
-
- Wang Q, Yang J, Wang Y, et al. Lutetium177-labeled DOTA-Ibandronate: a novel radiopharmaceutical for targeted treatment of bone metastases. Mol Pharm . 2023;20:1788–1795.
-
- Liu H, Liu L, Fu W, et al. 18 F-NaF uptake in breast cancer. Clin Nucl Med . 2020;45:878–879.
-
- Kothekar E, Raynor WY, Al-Zaghal A, et al. Incidental 18 F-NaF uptake in drug-induced gynecomastia. Clin Nucl Med . 2019;44:e303–e304.
-
- Al-Zaghal A, Werner TJ, Høilund-Carlsen PF, et al. The detection of uterine leiomyoma (fibroid) calcifications on 18 F-NaF PET/CT. Clin Nucl Med . 2018;43:e287–e288.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
